CompletedPhase 3NCT02230566
A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)
Studying Mucopolysaccharidosis type 7
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Ultragenyx Pharmaceutical Inc
- Principal Investigator
- Paul Harmatz, MDUCSF Benioff Children's Hospital Oakland
- Intervention
- UX003(drug)
- Enrollment
- 12 enrolled
- Eligibility
- 5-35 years · All sexes
- Timeline
- 2014 – 2016
Study locations (4)
- Children's Hospital Oakland, Oakland, California, United States
- Children's Hospital of Orange County, Orange, California, United States
- Miami Children's Hospital, Miami, Florida, United States
- University of Minnesota, Minneapolis, Minnesota, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02230566 on ClinicalTrials.gov